Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.

导出 OA

翻译打印收藏纠错

作者： Donavan T,Cheng ^[1] ; Meera,Prasad ^[2] ; Yvonne,Chekaluk ^[1] ; Ryma,Benayed ^[3] ; Justyna,Sadowska ^[1] ; Ahmet,Zehir ^[1] ; Aijazuddin,Syed ^[1] ; Yan Elsa,Wang ^[1] ; Joshua,Somar ^[1] ; Yirong,Li ^[1] ; Zarina,Yelskaya ^[1] ; Donna,Wong ^[1] ; Mark E,Robson ^[1] ; Kenneth,Offit ^[4] ; Michael F,Berger ^[4] ; Khedoudja,Nafa ^[1] ; Marc,Ladanyi ^[5] ; Liying,Zhang ^[1]

作者单位： Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 36, New York, NY, 10065, USA. ^[1] Illumina Inc, Santa Clara, CA, USA. ^[2] Brigham and Women's Hospital, Boston, MA, USA. ^[3] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[4] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[5] Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 36, New York, NY, 10065, USA. ladanyim@mskcc.org. ^[6] Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ladanyim@mskcc.org. ^[7] Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 36, New York, NY, 10065, USA. zhangl2@mskcc.org. ^[8]